公开(公告)号：US20020193309A1

公开(公告)日：2002-12-19

申请号：US10212357

申请日：2002-08-02

Applicant: Yeda Research and Development Co., Ltd., an Israel corporation

Inventor： Avner Yayon

IPC: G01N033/567 ,  C12P021/02 ,  C12N005/06 ,  A61K038/18 ,  C07K014/50

CPC classification number: G01N33/566 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/50 ,  C07K16/2863 ,  G01N33/53 ,  G01N33/56966 ,  G01N33/6887 ,  G01N33/74 ,  G01N2333/50 ,  G01N2333/9121

Abstract: The present invention concerns fibroblast growth factor 9 (FGF9) as a high affinity ligand for fibroblast growth factor receptor 3 (FGFR3) which ligand is capable of binding and activating FGFR3 in a specific manner. The present invention is also directed to methods for detection of FGFR3 by utilizing FGF9, as well as to pharmaceutical compositions for modulating the activity of FGFR3 comprising as an active ingredient FGF9, antagonists thereof or FGF binding agents which are capable of neutralizing native circulating FGF9. The present invention further concerns novel recombinant mouse and chicken FGF9, expression vectors comprising these recombinant FGF9s and a transgenic animal transformed with said expression vectors.

Abstract translation: 本发明涉及作为成纤维细胞生长因子受体3（FGFR3）的高亲和力配体的成纤维细胞生长因子9（FGF9），该配体能够以特异性方式结合并活化FGFR3。 本发明还涉及通过利用FGF9检测FGFR3的方法，以及用于调节FGFR3活性成分的药物组合物，其包含能够中和天然循环FGF9的活性成分FGF9，其拮抗剂或FGF结合剂。 本发明还涉及新型重组小鼠和鸡FGF9，包含这些重组FGF9的表达载体和用所述表达载体转化的转基因动物。